Abstract
To the Editor: We read with interest the Editorial by Norris and Barnett1 on the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. They conclude that aspirin is still the first choice in the secondary prevention of stroke, that clopidogrel is only marginally more effective than aspirin in secondary prevention of vascular end points, and that there is no convincing evidence that clopidogrel (either alone or combined with aspirin) improves the outcome in patients presenting with TIA or stroke with a cost that is 80 times that of aspirin alone.1 The Canadian Cooperative Study Group already in 1978 had observed that among men the fewest events occurred …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
